Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Equity Average (2020 - 2025)

Oncology Institute's Equity Average history spans 6 years, with the latest figure at -$14.0 million for Q4 2025.

  • For Q4 2025, Equity Average fell 246.79% year-over-year to -$14.0 million; the TTM value through Dec 2025 reached -$14.0 million, down 246.79%, while the annual FY2025 figure was -$6.1 million, 120.01% down from the prior year.
  • Equity Average reached -$14.0 million in Q4 2025 per TOI's latest filing, down from -$10.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $128.0 million in Q2 2022 to a low of -$14.0 million in Q4 2025.
  • Average Equity Average over 5 years is $57.4 million, with a median of $49.1 million recorded in 2021.
  • Peak YoY movement for Equity Average: surged 2200.61% in 2021, then crashed 246.79% in 2025.
  • A 5-year view of Equity Average shows it stood at $75.8 million in 2021, then soared by 65.54% to $125.6 million in 2022, then tumbled by 48.68% to $64.4 million in 2023, then tumbled by 85.2% to $9.5 million in 2024, then plummeted by 246.79% to -$14.0 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Equity Average are -$14.0 million (Q4 2025), -$10.6 million (Q3 2025), and -$2.0 million (Q2 2025).